Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)
European Journal of Cancer(2019)
Abstract
•Radiochemotherapy remains the standard treatment for anal cancer since the ‘90s.•Our results suggest that a longer overall treatment time may be detrimental to outcome.•In the dose range of 50.4–59 Gy, lower doses seem to be preferred.•A longer than 2-week gap might be detrimental.•Findings may guide trials to define optimal overall treatment time and dose level.
MoreTranslated text
Key words
Anal cancer,Radiation,Overall treatment time,Chemoradiation
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined